Details of Disease

General Information of Disease (ID: DIS162FN)

• Disease Name: Diabetic macular edema
• Disease Class: 9B71: Retinopathy
• Disease Hierarchy:
  DISHGUJM: Diabetic retinopathy
  DIS162FN: Diabetic macular edema
• ICD Code:
  ICD-11: ICD-11: 9B71.02
  Expand ICD-11: '9B71.02
  Expand ICD-9: 250,362.01,362.07,362.53,782.3
• Disease Identifiers:
  MONDO ID: MONDO_0004728
  UMLS CUI: C0730285
  MedGen ID: 676494
  SNOMED CT ID: 312912001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aflibercept	DMT3D5I	Approved	NA	[1]
Brolucizumab	DMW8QNG	Approved	Antibody	[2]
Faricimab	DM83SEB	Approved	Antibody	[3]
Paramethasone	DM6PR40	Approved	Small molecular drug	[4]
Ranibizumab	DMSYPNW	Approved	Antibody	[5]
Teprotumumab	DM4L59B	Approved	NA	[6]

This Disease is Treated as An Indication in 24 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KH-902	DM8VO16	Phase 3	NA	[7]
KSI-301	DMM2LTC	Phase 3	Antibody biopolymer conjugate	[8]
M710	DM1PRT6	Phase 3	Small molecular drug	[9]
Squalamine	DM3PS2E	Phase 3	Small molecular drug	[6]
Abicipar pegol	DM59OJ2	Phase 2	NA	[6]
AKB-9778	DMKNRYH	Phase 2	NA	[6]
ALG-1001	DMR2YPF	Phase 2	NA	[10]
ASP8232	DMYK1JU	Phase 2	NA	[6]
BI 1026706	DMAXIXH	Phase 2	NA	[6]
Cibinetide	DMCFLRH	Phase 2	NA	[6]
HCB1019	DMX8C6J	Phase 2	Small molecular drug	[11]
KVD001	DMK4VOU	Phase 2	NA	[12]
KVD824	DM5N4OA	Phase 2	NA	[13]
LKA651	DMCFGP3	Phase 2	Antibody	[14]
OPT-302	DMS4XFI	Phase 2	NA	[15]
PF-04523655	DMA9MBR	Phase 2	siRNA drug	[16]
PF-655	DM527T4	Phase 2	NA	[16]
RO6867461	DML2SO5	Phase 2	NA	[6]
Safotibant	DMKDP57	Phase 2	Small molecular drug	[17]
THR-149	DMW8X05	Phase 2	Small molecular drug	[18]
SF0166	DM4NK3J	Phase 1/2	NA	[6]
IBI-20089	DMYBHIR	Phase 1	NA	[6]
ICo-007	DM79W8K	Phase 1	Antisense drug	[19]
THR-687	DMHRY8A	Phase 1	Small molecular drug	[20]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CLT-003	DMRV5IQ	Investigative	NA	[21]
NCX-434	DM0ZZMY	Investigative	NA	[21]
RAGE-immunoglobulin fusion protein	DMKNR5O	Investigative	NA	[21]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AMD1	TTBFROQ	Strong	Genetic Variation	[22]
KLKB1	TTN0PCX	Strong	Biomarker	[23]
PCSK2	TT46F0P	Strong	Genetic Variation	[24]
PLA2G7	TTDNFMT	Strong	Biomarker	[25]
RS1	TTT2CZY	Strong	Altered Expression	[26]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35A1	DTVZIRG	Strong	Biomarker	[27]

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
HYLS1	OT3SW5UC	Limited	Genetic Variation	[28]
TDRD9	OTS4UBI8	Limited	Genetic Variation	[28]
CIAO3	OT0V91PK	Strong	Biomarker	[29]
GAL3ST1	OTSFFZRD	Strong	Biomarker	[27]
HGS	OTCYYCAC	Strong	Biomarker	[30]
MALRD1	OTCAAPVO	Strong	Genetic Variation	[24]
NAP1L1	OTI7WBZV	Strong	Biomarker	[31]
PLVAP	OTAQGWYA	Strong	Biomarker	[32]
PLXNA2	OTNNBJMQ	Strong	Biomarker	[33]
RPE	OT0XT3JU	Strong	Biomarker	[34]
SRSF5	OTC5WP98	Strong	Biomarker	[30]

References

• [1] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
• [2] ClinicalTrials.gov (NCT04058067) To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). U.S. National Institutes of Health.
• [3] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761235.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023 Mar-Apr;68(2):147-174.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT04603937) A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER). U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of Allegro Ophthalmics.
• [11] Clinical pipeline report, company report or official report of OcuNexus Therapeutics.
• [12] ClinicalTrials.gov (NCT03466099) Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME). U.S. National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
• [14] ClinicalTrials.gov (NCT03927690) Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT03345082) A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT01445899) PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME). U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01319487) Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT04527107) A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI). U.S. National Institutes of Health.
• [19] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [20] ClinicalTrials.gov (NCT03666923) A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME). U.S. National Institutes of Health.
• [21] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [22] Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):186-190. doi: 10.3928/23258160-20180221-06.
• [23] Retinal proteome associated with bradykinin-induced edema.Exp Eye Res. 2019 Sep;186:107744. doi: 10.1016/j.exer.2019.107744. Epub 2019 Jul 24.
• [24] Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy.BMC Med Genet. 2018 May 8;19(1):71. doi: 10.1186/s12881-018-0587-8.
• [25] Lipoprotein-associated phospholipase A2: The story continues.Med Res Rev. 2020 Jan;40(1):79-134. doi: 10.1002/med.21597. Epub 2019 May 29.
• [26] Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6234-6241. doi: 10.1167/iovs.16-20157.
• [27] Glucose-regulated protein 78 in the aqueous humor in diabetic macular edema patients.Medicine (Baltimore). 2018 Nov;97(45):e12757. doi: 10.1097/MD.0000000000012757.
• [28] Low health literacy levels in patients with chronic retinal disease.BMC Ophthalmol. 2019 Aug 8;19(1):174. doi: 10.1186/s12886-019-1191-1.
• [29] Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1857-1865. doi: 10.1007/s00417-018-4072-z. Epub 2018 Jul 23.
• [30] Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.Acta Ophthalmol. 2017 Aug;95(5):464-471. doi: 10.1111/aos.13294. Epub 2016 Oct 24.
• [31] Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema.J Clin Invest. 2019 Nov 1;129(11):4593-4608. doi: 10.1172/JCI120879.
• [32] An anti-PLVAP antibody suppresses laser-induced choroidal neovascularization in monkeys.Eur J Pharmacol. 2019 Jul 5;854:240-246. doi: 10.1016/j.ejphar.2019.04.035. Epub 2019 Apr 23.
• [33] Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids.Acta Diabetol. 2020 Mar;57(3):287-296. doi: 10.1007/s00592-019-01424-4. Epub 2019 Sep 21.
• [34] Aqueous humour concentrations of PEDF and Erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema.Biosci Rep. 2019 Jun 18;39(6):BSR20190328. doi: 10.1042/BSR20190328. Print 2019 Jun 28.